Resource use and costs in patients with poorly controlled type 2 diabetes mellitus and obesity in routine clinical practice in Spain

Abstract

Objective: To compare healthcare resource use (HRU) and annual costs in type 2 diabetes mellitus (T2DM) patients with poor glycaemic control and obesity versus good glycaemic control without obesity. Methods: Observational retrospective study based on the analysis of electronic medical records from the BIG-PAC database, with one year of follow-up. T2DM patients aged 30 years who requested medical care during 2013 were included. Annual HRU and costs per patient were compared between a reference group (HbA1c 8%, BMI 30 kg/m 2 , receiving 2 oral antidiabetic drugs [OADs]) and a control group (HbA1c < 7% and BMI <30 kg/m 2 ). Direct and indirect costs (lost productivity) were analysed. Cost comparisons across groups were made using the analysis of covariance (ANCOVA) for each cost component, with age, sex, time from diagnosis, Charlson comorbidity index, OAD number and sex by group interaction as covariates.Results: During the follow-up, patients in the reference group (N ¼ 2709) had a greater HRU than those in the control group (N ¼ 5266), especially in the number of primary care (PC) visits (11.8 vs. 9.8;

Disease and Economic Burden of Poor Metabolic and Weight Control in Type 2 Diabetes in Spain: A Systematic Literature Review

“…Regarding the correct communication of the information, two of the nine studies had 90.1% of STROBE items adequately reported [ 27 , 29 ], followed by three others with 81.8% [ 23 – 25 ] and two additional one with 77.3% [ 26 , 28 ]. Lower STROBE percentages (68.2%) were found for two of the selected publications [ 30 , 31 ] because of the absence or lack of clarity around essential study aspects, such as study design, variables, statistical methods or sample size (Table 1 ).…”

“…Healthcare resource use and associated direct and total medical costs were higher in PwT2D HbA1c ≥ 8% with a BMI ≥ 30 kg/m 2 than in those HbA1c < 7% with normal weight, mainly driven by an increase in primary care medical visits, medicines and hospitalization costs (Fig. 3 and table S5) [ 29 ].…”

C-peptide level as predictor of type 2 diabetes remission and body composition changes in non-diabetic and diabetic patients after Roux-en-Y gastric bypass

“…Despite new pharmaceutical treatment options for T2DM, their cost limits their widespread use, especially in underdeveloped countries. Moreover, T2DM control has been inadequate worldwide ( 3 - 5 ).…”